Maurizio Simmaco
Full Professor Molecular Biology - Director Diparmet Diagnostic sciences
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Year:
2026
Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7
Year:
2026
Collaborators (19)
Fabio Puglisi
Head of the Unit of Medical Oncology and Cancer Prevention
-
Valentina Guarneri
Associate Professor
University of Padova
Marina BORRO
Associate Professor - Biochemistry
Sapienza University of Rome
Umberto Malapelle
-
Edoardo Crimini
Medical Oncologist
European Institute of Oncology
Giuseppe Tonini
Full Professor of Medical Oncology
Campus Bio Medico University Hospital
Giuseppe Giannini
Head, Unit of Advanced Molecular Diagnostic in Oncology
Sapienza University
Lucia Del Mastro
dirigente medico
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro
Andrea DeCensi
Director
Champalimaud Foundation
Giancarlo Pruneri
University of Milan
Giuseppe Curigliano
European Institute of Oncology
Lidia Strigari
Head of Department
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Alberto Zambelli
Associate Professor
University of Milano-Bicocca
Paolo Marchetti
Sapienza University of Rome
SIMONA PISEGNA
Sapienza University of Rome
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
PIERFRANCO CONTE
Professore di 1^ fascia
University of Padova
Chiara Cremolini
University Hospital of Pisa
Make your next move.
Prepare your application
Review drafts before you send them.